SARS COV2 vaccine ResPonse In Obesity - SCORPIO study

保护人们免受COVID-19感染的最佳方法是接种疫苗。疫苗会触发人的免疫系统，这样当人再次接触病毒时，免疫系统就会做出有效的反应。重要的是要知道，针对导致COVID-19的SARS-CoV-2病毒的疫苗对有潜在健康问题的人是否像对健康人一样有效。这项研究的目的是测试SARS-CoV-2疫苗是否对体重问题和糖尿病患者同样有效。超重/肥胖人群和糖尿病患者如果感染COVID-19，更有可能患上重病。如果疫苗不起作用，那么当英国有1000万人认为自己受到保护时，他们仍将面临感染COVID-19的高风险。通过汇集世界领先的肥胖/糖尿病和感染/免疫领域的医生和研究人员，该研究项目将确定超重或糖尿病患者的免疫反应是否不同。先前对流感疫苗等其他疫苗的研究表明，有这些健康状况的人的免疫反应可能更弱，或者可能持续的时间不长。我们认为，一些肥胖/糖尿病患者的免疫反应可能较弱，我们想看看减肥是否能增强疫苗的反应。如果确实如此，那么这将为减肥治疗提供额外的帮助和支持，这将是一个强有力的激励，目前只有少数人真正与体重斗争了几十年。在接下来的一年里，我们将邀请200名正在接受不同减肥治疗（高强度饮食和手术）的人参加天蝎座研究，这是他们日常医疗护理的一部分。如果他们同意，我们将采集一些额外的血液样本，看看他们的疫苗反应在减肥治疗后是否会发生变化。我们将收集有关他们的身高、体重、医疗状况的信息，并详细检查免疫系统、血糖水平和激素。根据我们的经验，可能有些人会减掉少量的体重，而另一些人会减掉很多体重。我们将研究体重减轻对第一剂和第二剂COVID-19疫苗免疫反应的影响。我们将在参与研究的人定期就诊期间密切关注他们，如果他们出现COVID-19感染症状，我们将确保他们得到及时的医疗护理。我们还将安排基因测序，看看这种病毒的特定变体是否会影响有体重问题和糖尿病的人。我们将把这些结果与当地体重正常的人进行比较，并将这些结果与全国各地的同事进行比较，以最大限度地利用现有信息。在研究结束时，我们将确定肥胖/糖尿病患者的免疫反应是否较弱，哪些人群的风险最大（例如，是血糖最高的人吗？），并找出减肥是否可以迅速改善对疫苗的免疫反应。让人们更好地抵御COVID-19。

The best way to protect people from COVID-19 is by vaccination. Vaccines trigger a person's immune system so it is primed to respond efficiently if the person comes into contact with the virus again. It is important to know whether vaccines against the SARS-CoV-2 virus, which causes COVID-19, work as well in people with underlying health conditions as they do in healthy people. The aim of this study is to test whether the SARS-CoV-2 vaccine works equally well in people with weight problems and diabetes. People who are overweight/obese and those who have diabetes are much more likely to become seriously ill if they develop COVID-19 infection. If vaccines don't work as well, then 10 million people in the UK will still be at high risk of COVID-19 infection, when they think they are protected. By bringing together world-leading doctors and researchers in obesity/diabetes and infection/immunity, this research project will establish whether the immune response is different in people who are overweight or have diabetes. Previous research with other vaccines such as the flu vaccine, suggests that the immune response might be weaker or may not last as long in people with these health conditions. We think it is likely that some people with obesity/diabetes will have a weak immune response and we want to see if losing weight can boost the vaccine response. If it does, then this would provide a strong incentive for extra help and support for weight loss treatments, which are currently only available to a small number of people who have really struggled with their weight for decades. Over the next year, we will invite 200 people who are having different weight loss treatments (intense diet and surgery) as part of their routine medical care to take part in the SCORPIO study. If they agree, we will take a few extra blood samples to look at whether their vaccine response changes after weight loss treatment. We will collect information about their height and weight, medical conditions and look in detail at the immune system, blood sugar levels and hormones. Based on our experience, it is likely some people will lose a small amount of weight while others will lose a lot of weight. We will study the impact of weight loss on the immune response to the first and second dose of the COVID-19 vaccine. We will keep a close eye on people in the study during their regular clinic visits and if they develop symptoms of COVID-19 infection, we will ensure they receive prompt medical care. We will also arrange for genetic sequencing to see if particular variants of the virus are affecting people with weight problems and diabetes.We will compare these results with normal weight people based locally and compare these results with colleagues around the country to make best use of the available informationAt the end of the study, we will establish whether the immune response is weaker in people with obesity/diabetes, which groups of people are most at risk (e.g. is it people with the highest blood sugars?) and find out if weight loss can rapidly improve the immune response to the vaccine, giving people better protection against COVID-19.